|
minimal PBPK in PML with IV PO dosing why is F calculated for IV?
|
|
8
|
7865
|
February 4, 2019
|
|
Materials from session about NONMEM-NLME: PD Time-to-event Analysis
|
|
0
|
13134
|
December 13, 2018
|
|
Materials from session about NONMEM-NLME: PD Categorical Response
|
|
0
|
12380
|
November 23, 2018
|
|
Q&A from session about PKPD 1comp-Emax with baseline, shape and effect
|
|
0
|
8401
|
July 13, 2018
|
|
Materials from session about NONMEM-NLME PKPD 1comp-Emax,baseline,shape and effect
|
|
0
|
13057
|
July 13, 2018
|
|
Q&A from session about NONMEM-NLME Indirect Response with IV Bolus
|
|
0
|
7754
|
July 3, 2018
|
|
Materials from session about NONMEM-NLME Indirect Response with IV Bolus
|
|
0
|
12075
|
July 3, 2018
|
|
Materials from NONMEM-NLME PD Emax inhibitory model with baseline and shape
|
|
0
|
11493
|
June 12, 2018
|
|
Materials for running NONMEM and Phoenix NLME in the cloud
|
|
0
|
12608
|
May 24, 2018
|
|
Q&A from session about nonlinear elimination model and bootstrap
|
|
0
|
7598
|
May 24, 2018
|
|
Materials from mixed absorption and model validation with VPC
|
|
0
|
12104
|
May 24, 2018
|
|
Materials from NONMEM-NLME session about nonlinear elimination model and bootstrap
|
|
0
|
12265
|
May 24, 2018
|
|
NONMEM-NLME Comparisons:TMDD Model translated from NONMEM (NM-TRAN) to Phoenix NLME (PML)
|
|
0
|
22415
|
March 22, 2018
|
|
Q&A from second session NONMEM-2-NLME: 2-compartment oral with categorical covariate
|
|
0
|
9163
|
March 13, 2018
|
|
Clearance scaling with individual body weight?
|
|
3
|
8751
|
March 12, 2018
|
|
NONMEM-NLME Comparisons: 2-compartment oral with categorical covariate
|
|
0
|
13977
|
March 8, 2018
|
|
Q&A from second session NONMEM-2-NLME: 2Comp Plasma Urine
|
|
0
|
8360
|
February 26, 2018
|
|
NONMEM-NLME Comparisons: 2-compartment IV Bolus Multiple Dose Plasma Urine
|
|
0
|
13808
|
February 23, 2018
|
|
Q&A from Intro-Session of NONMEM-NLME Comparisons
|
|
0
|
8737
|
February 10, 2018
|
|
NONMEM-NLME Comparisons 1: Intro & 1-compartment IV Bolus FOCE
|
|
0
|
12902
|
February 9, 2018
|
|
Q&A from Adaptive Trial Simulation session
|
|
0
|
8999
|
December 20, 2017
|
|
Q&A from session about TMDD QE Model
|
|
0
|
9448
|
December 18, 2017
|
|
Q&A from session about mPBPK Model
|
|
0
|
8129
|
December 15, 2017
|
|
Adaptive Simulations: Extending PML to Trial Simulations
|
|
1
|
16396
|
December 14, 2017
|
|
Target-mediated Drug Disposition (TMDD) Modeling Using the Quasi-equilibrium Assumption
|
|
1
|
15496
|
December 1, 2017
|
|
Minimal physiologically-based pharmacokinetic model for monoclonal antibodies
|
|
1
|
13642
|
November 17, 2017
|
|
Q&A from Lesson 20: Transduction Modeling
|
|
0
|
8402
|
August 11, 2017
|
|
Lesson 20: Transduction Modeling
|
|
0
|
16364
|
August 11, 2017
|
|
Q&A from Lesson 19: Dose-response-time analysis
|
|
0
|
9090
|
July 28, 2017
|
|
Lesson 19: Dose-response-time analysis
|
|
0
|
15181
|
July 28, 2017
|